GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.40
Bid: 1.40
Ask: 1.44
Change: -0.005 (-0.35%)
Spread: 0.04 (2.857%)
Open: 1.40
High: 1.40
Low: 1.40
Prev. Close: 1.425
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Circular & Convening of EGM

1 Dec 2022 07:00

RNS Number : 1152I
RTW Venture Fund Limited
01 December 2022
 

LEI: 549300Q7EXQQH6KF7Z84

1 December 2022

RTW Venture Fund Limited

Publication of Circular & Convening of EGM

Further to the announcement on 28 November 2022, RTW Venture Fund Limited (the "Company") announces that documentation has been filed with the U.S. Internal Revenue Service to change the Company's tax status, with effect from 1 December 2022, from a "publicly traded partnership" or "PTP" to a corporation for U.S. federal tax purposes ("Tax Election").

A shareholder circular (the "Circular") has been published today on the Company's website at www.rtwfunds.com/venture-fund. In addition,  a copy of the Circular has been submitted to the National Storage Mechanism and will shortly be available for viewing online at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

A notice of an Extraordinary General Meeting ("EGM") is contained in the Circular. At the EGM, Shareholders will be asked (a) to approve the adoption of new articles of incorporation, which will be updated to reflect the U.S. federal tax status of the Company following completion of the Tax Election and the reorganisation; and (b) to ratify the decision of the Board to make the Tax Election.

This information is not intended to be all-inclusive or to render specific professional tax advice. Shareholders are urged to consult with their independent tax advisors to determine the tax consequences. The Company does not provide tax or legal advice.

For Further Information:

RTW Investments, LP

+44 (0) 77 1741 7711

Woody Stileman, Managing Director

Buchanan

+44 (0)20 7466 5107

Charles Ryland

Henry Wilson

George Beale

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

Jérémie Birnbaum

James Bouverat (Sales)

BofA Securities

+44 (0) 20 7628 1000

Edward Peel

Kieran Millar

Elysium Fund Management Limited

+44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

Morgan Stanley Fund Services USA LLC

+1 (914) 225 8885

 

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFDDFDSEESEDF
Date   Source Headline
10th Dec 20207:00 amRNSTransformational Update from Largest Holding
8th Dec 20208:03 amRNSNew Investment in Nuance Pharma
1st Dec 20207:00 amRNSTotal Voting Rights
16th Nov 20205:59 pmRNSIssue of Equity
13th Nov 20206:22 pmRNSAnnouncement of Share Issuance
13th Nov 20207:00 amRNSNet Asset Value(s)
10th Nov 20209:26 amRNSHolding(s) in Company
9th Nov 20202:00 pmRNSNew Investment in Prometheus Biosciences
2nd Nov 20207:00 amRNSTotal Voting Rights
28th Oct 20201:25 pmRNSHolding(s) in Company
19th Oct 20207:01 amRNSTarsus Pharmaceuticals Prices $88 Million IPO
19th Oct 20207:00 amRNSQuarterly Update
16th Oct 20205:19 pmRNSIssue of Equity
14th Oct 20202:31 pmRNSAnnouncement of Share Issuance
14th Oct 20207:00 amRNSNet Asset Value(s)
5th Oct 20207:00 amRNSC4 Therapeutics Prices $182 Million IPO
2nd Oct 20207:00 amRNSPulmonx Prices $190 Million IPO
28th Sep 20204:13 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSInterim Report for the period ended 30 June 2020
21st Sep 20207:00 amRNSAthira Pharma Prices $204.0 Million IPO
15th Sep 20207:00 amRNSNet Asset Value(s)
14th Sep 20201:00 pmRNSSeries B Financing Round in NiKang Therapeutics
2nd Sep 20207:00 amRNSNotice of Interim Report
1st Sep 20207:00 amRNSTotal Voting Rights
17th Aug 20205:16 pmRNSIssue of Equity
14th Aug 20202:01 pmRNSAnnouncement of Share Issuance
14th Aug 20207:00 amRNSNet Asset Value(s)
12th Aug 20207:00 amRNSPortfolio Company Update
3rd Aug 20207:00 amRNSTotal Voting Rights
28th Jul 20206:25 pmRNSHolding(s) in Company
27th Jul 20207:00 amRNSiTeos Therapeutics Prices $201 Million IPO
23rd Jul 202012:00 pmRNSNew Investment in Milestone Pharmaceuticals
22nd Jul 20201:00 pmRNSSeries D Financing in Encoded Therapeutics
21st Jul 20207:00 amRNSQuarterly Update
17th Jul 202011:44 amRNSIssue of Equity - Replacement Announcement
17th Jul 20207:00 amRNSIssue of Equity
16th Jul 20206:08 pmRNSAnnouncement of further Share Issuance
16th Jul 20207:00 amRNSIssue of Equity
15th Jul 20207:00 amRNSNet Asset Value(s)
25th Jun 20206:08 pmRNSResult of AGM
22nd Jun 20201:59 pmRNSAGM Statement
16th Jun 20201:15 pmRNSSeries B Financing in C4 Therapeutics
16th Jun 20207:00 amRNSUpdate on Avidity Biosciences IPO
12th Jun 20209:33 amRNSAvidity Biosciences Prices $259.2 Million IPO
12th Jun 20207:00 amRNSNet Asset Value(s)
4th Jun 202012:30 pmRNSSeries B Financing in Athira Pharma
1st Jun 20207:00 amRNSTotal Voting Rights
21st May 20204:00 pmRNSNotice of AGM
19th May 20205:40 pmRNSIssue of Equity
18th May 20207:00 amRNSAnnouncement of Share Issuance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.